EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 32 / Numéro 3 (Mars 2016) Med Sci (Paris), 32 3 (2016) 253-259 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 32, Numéro 3, Mars 2016
Page(s) 253 - 259
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20163203009
Publié en ligne 23 mars 2016
  1. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011 ; 365 : 620–628. [CrossRef] [PubMed] [Google Scholar]
  2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol 2004 ; 9 : 136–139. [CrossRef] [Google Scholar]
  3. Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006 ; 155 : 729–736. [CrossRef] [PubMed] [Google Scholar]
  4. Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007 ; 8 : 639–646. [CrossRef] [PubMed] [Google Scholar]
  5. Leung-Theung-Long S, Guerder S. Les cellules Th17 cells, une nouvelle population de cellules T CD4 effectrices pro-inflammatoires. Med Sci (Paris) 2008 ; 24 : 972–976. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. Yssel H, Bensussan A. Existe-t-il dans la peau une nouvelle population lymphocytaire Th22 distincte des lymphocytes Th17 ? Med Sci (Paris) 2010 ; 26 : 12–14. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  7. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006 ; 441 : 235–238. [CrossRef] [PubMed] [Google Scholar]
  8. Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003 ; 278 : 1910–1914. [CrossRef] [PubMed] [Google Scholar]
  9. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005 ; 201 : 233–240. [CrossRef] [PubMed] [Google Scholar]
  10. Ma HL, Liang S, Li J, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008 ; 118 : 597–607. [PubMed] [Google Scholar]
  11. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008 ; 371 : 1665–1674. [CrossRef] [PubMed] [Google Scholar]
  12. Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2015 ; 136 : 116–124.e7. [CrossRef] [PubMed] [Google Scholar]
  13. Papp K, Thaçi D, Reich K, et al. Tildrakizumab (MK-3222), an anti- IL-23p19 monoclonal antibody, improves psoriasis in a phase 2b randomized placebo-controlled trial. Br J Dermatol 2015 ; 173 : 930–939. [CrossRef] [PubMed] [Google Scholar]
  14. Kopp T, Riedl E, Bangert C, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 2015 ; 521 : 222–226. [CrossRef] [PubMed] [Google Scholar]
  15. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006 ; 36 : 1309–1323. [CrossRef] [PubMed] [Google Scholar]
  16. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007 ; 445 : 648–651. [CrossRef] [PubMed] [Google Scholar]
  17. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013 ; 168 : 412–421. [CrossRef] [PubMed] [Google Scholar]
  18. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012 ; 366 : 1190–1199. [CrossRef] [PubMed] [Google Scholar]
  19. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012 ; 366 : 1181–1189. [CrossRef] [PubMed] [Google Scholar]
  20. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J Exp Med 2005 ; 202 : 135–143. [CrossRef] [PubMed] [Google Scholar]
  21. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008 ; 128 : 1207–1211. [CrossRef] [PubMed] [Google Scholar]
  22. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000 ; 13 : 715–725. [CrossRef] [PubMed] [Google Scholar]
  23. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003 ; 421 : 744–748. [CrossRef] [PubMed] [Google Scholar]
  24. Yawalkar N, Karlen S, Hunger R, et al. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998 ; 111 : 1053–1057. [CrossRef] [PubMed] [Google Scholar]
  25. Bruch-Gerharz D, Fehsel K, Suschek C, et al. A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes. J Exp Med 1996 ; 184 : 2007–2012. [CrossRef] [PubMed] [Google Scholar]
  26. Goebeler M, Toksoy A, Spandau U, et al. The C-X-C chemokine Mig is highly expressed in the papillae of psoriatic lesions. J Pathol 1998 ; 184 : 89–95. [CrossRef] [PubMed] [Google Scholar]
  27. Gottlieb AB, Luster AD, Posnett DN, Carter DM. Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques. J Exp Med 1988 ; 168 : 941–948. [CrossRef] [PubMed] [Google Scholar]
  28. Griffiths CE, Voorhees JJ, Nickoloff BJ. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 1989 ; 20 : 617–629. [CrossRef] [PubMed] [Google Scholar]
  29. Lemster BH, Carroll PB, Rilo HR, et al. IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin Exp Immunol 1995 ; 99 : 148–154. [CrossRef] [PubMed] [Google Scholar]
  30. Groves RW, Ross EL, Barker JN, MacDonald DM. Vascular cell adhesion molecule-1: expression in normal and diseased skin and regulation in vivo by interferon gamma. J Am Acad Dermatol 1993 ; 29 : 67–72. [CrossRef] [PubMed] [Google Scholar]
  31. Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003 ; 102 : 161–168. [CrossRef] [PubMed] [Google Scholar]
  32. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004 ; 199 : 125–130. [CrossRef] [PubMed] [Google Scholar]
  33. Luo J, Wu S-J, Lacy ER, et al. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol 2010 ; 402 : 797–812. [CrossRef] [PubMed] [Google Scholar]
  34. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007 ; 8 : 950–957. [CrossRef] [PubMed] [Google Scholar]
  35. Segura E, Touzot M, Bohineust A, et al. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 2013 ; 38 : 336–348. [CrossRef] [PubMed] [Google Scholar]
  36. Brembilla NC, Montanari E, Truchetet M-E, et al. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther 2013 ; 15 : R151. [CrossRef] [PubMed] [Google Scholar]
  37. Cheung PFY, Wong CK, Lam CWK. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation. J Immunol 2008 ; 180 : 5625–5635. [CrossRef] [PubMed] [Google Scholar]
  38. Schwarzenberger P, Huang W, Ye P, et al. Requirement of endogenous stem cell factor and granulocyte-colony-stimulating factor for IL-17-mediated granulopoiesis. J Immunol 2000 ; 164 : 4783–4789. [CrossRef] [PubMed] [Google Scholar]
  39. Ogura H, Murakami M, Okuyama Y, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008 ; 29 : 628–636. [CrossRef] [PubMed] [Google Scholar]
  40. Farhi D, Dupin N. Les biothérapies dans le psoriasis. Presse Med 2009 ; 38 : 832–843. [CrossRef] [PubMed] [Google Scholar]
  41. Viguier M, Richette P, Bachelez H, et al. Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders. Exp Rev Clin Immunol 2009 ; 5 : 421–431. [CrossRef] [Google Scholar]
  42. Tauber M, Beneton N, Reygagne P, et al. Alopecia areata developing during ustekinumab therapy: report of two cases. Eur J Dermatol 2013 ; 23 : 912–913. [PubMed] [Google Scholar]
  43. Tauber M, Buche S, Reygagne P, et al. Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol 2014 ; 70 : 1146–1149. [CrossRef] [PubMed] [Google Scholar]
  44. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008 ; 57 : 1639–1641. [CrossRef] [PubMed] [Google Scholar]
  45. Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015 ; 386 : 541–551. [CrossRef] [PubMed] [Google Scholar]
  46. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med 2014 ; 371 : 326–338. [CrossRef] [PubMed] [Google Scholar]
  47. Bonnet MC, Bagot M, Bensussan A. Anticorps monoclonaux ciblant l’IL-17A ou son récepteur dans le psoriasis : une nouvelle approche thérapeutique ? Med Sci (Paris) 2012 ; 28 : 1035–1037. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  48. Bachelez H, van de Kerkhof PC, Strohal R, et al. OPT compare investigators. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 2015 ; 386 : 552–561. [CrossRef] [PubMed] [Google Scholar]
  49. Duhen T, Geiger R, Jarrossay D, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009 ; 10 : 857–863. [CrossRef] [PubMed] [Google Scholar]
  50. Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009 ; 10 : 864–871. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.